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Streptococcus pneumoniae is one of the most important 
human pathogens. In fact, it represents the most frequent 
cause of pneumonia, meningitis, sinusitis and otitis media.
The World Health Organization estimates that every 
year approximately 1.6 million individuals die from in-
vasive pneumococcal diseases. Up to 1 million of these 
deaths are children under 5 years of age. 
Pathogenesis of pneumococcal infections
Pneumonia is the most frequent infection caused by S. 
pneumoniae. Like every invasive infection it goes through 
different phases: adhesion and colonisation, invasion and 
inflammation, and in some cases, it can even give shock. 
In each of these phases the germ uses its virulence factors 
to overcome host defences: the capsule, the most impor-
tant, the bacterial wall, surface proteins (about 500) and 
finally, the hemolysine exotoxines secreted by the Pneu-
mococcus, of which pneumolisina is the strongest.
The first germ-host contact (adhesion) is carried out 
through the pili that ensure adherence to the epitheli-
um [1]. The cellular wall, rich in residues of phospho-
rycholine, plays a fundamental role in this process. It is 
the cellular wall that guarantees adhesion because the 
epithelial cells are rich in specific receptors for phospho-
rycholine. Surface proteins are also important. Among 
these there is an adhesin called PsaA or Pneumococcal 
surface adhesin codified as the psa gene. This gene in-
duces adhesion even indirectly, inducing the synthesis of 
a second adhesin, the CbpA or coline-binding-proteinA.
Once adhesion to the host has occurred, the result is colo-
nisation by that pathogenic agent. This colonisation, how-
ever, is not necessarily pathological. In fact, most patients 
colonised by S. pneumoniae remain carriers of pneumo-
coccus, developing a serotype-specific immune response.
The most well-known invasion phenomenon is pneumo-
nia that can also represent the source of a bacteremia or 
sepsis. The ability of invasion is much higher for envel-
oped germs and it varies according to the type of capsule 
(chemical-physical differences) [2]. The same opsiniza-
tion of the capsule by the complement is greater in some 
serotypes than in others. Serotypes which are poorly op-
sonized are phagocytized less and at the same time are 
less capable of inducing the production of specific an-
tibodies [3, 4]. In general, all capsular polysaccharides 
interfere with phagocytosis, limiting the opsonization 
mediated by some complement fractions, such as the 
C3b. However, the capsule by itself cannot determine 
the resistance to the immune defences and it cannot ex-
plain the invasiveness of the germ. Germs with identi-
cal capsules can have, in fact, a different invasiveness 
due to the presence of other virulence factors [5]. One 
example is represented by the antigen CbpA that plays 
an essential role in the passage through the blood-brain 
barrier.
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Summary
Streptococcus pneumoniae is one of the most important human 
pathogens. It represents the most frequent cause of pneumonia, 
meningitis, sinusitis and otitis.
After the PCV7 vaccine introduction, a serotypic switch was 
noticed. This phenomenon led to the replacement of the seven sero-
types contained in the vaccine with other less common ones, some 
of which are invasive or characterised by antibiotic-resistance. 
This replacement is only partially due to the vaccination. Many 
causes have been suggested to explain this effect: apearance of 
new serotypes, diffusion of minority serotypes and replacement of 
common serotypes due to natural secular trend.
Pneumococcus has a promiscuous “sex life”, characterized by 
homologous recombinations within the same species and also 
between different species. This fact can unlock the secret of how 
these pathogens can develop antibiotic or vaccine-resistance.
The serotypic switch involves big loci that are responsible for 
capsular polysaccharide synthesis. The most important region 
of the genome involved in this process is near the gene tetM. 
The same mechanisms are also responsible for antibiotic resist-
ance. In recent years the growth of penicillin, macrolides and 
clindamycine resistance has been noticed. It is also important 
to underline that multidrug-resistant bacteria isolation has 
increased.
In conclusion, to obtain more information about bacteria compo-
sition and evolution, antibiotic-resistance and vaccine response, 
it is fundamental to improve the epidemiological surveillance 
of pneumococcal infections using modern molecular diagnostic 
techinques.
The full article is free available on www.jpmh.org
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If the Pneumococcus manages to avoid phagocytosis, 
invasion begins that leads to the activation of the in-
flammatory cascade: the cascade of inflammatory cy-
tokines (IL-1, IL-6, TNF), the alternative complement 
pathway and the coagulation cascade. The bacterial 
wall has a fundamental role in inducing inflammation. 
Its various components, through various mechanisms, 
trigger the inflammatory response and the production 
of antibodies directed against the same bacterial wall 
thanks to the activation of lymphocytes B activated in 
turn by lymphocytes T CD4+, that are sensitive to the 
release of proinflammatory cytokines. An enhance-
ment of an inflammatory response is also caused by 
the release of pneumolysina (a hemolysin) by the Pnue-
mococcus. This carries out an offensive role creating 
pores on the inside of the double phospholipid layer 
of the membrane of the host cells, by exploiting the 
link with cholesterol residues present in human cells, 
inducing cell lysis. The pneumolysina is also capable 
of inducing the production of inflammatory cytokines 
and nitric oxide, inhibiting ciliary movement [6, 7]. It 
also induces complement activation and reduces the 
lymphocytic proliferative response and the bactericidal 
activity of the neutrophils.
Innate immunity plays a role of fundamental importance 
in the response against Pneumococcus and other Gram+ 
bacteria. In fact, the course of the illness is more severe 
in all those patients with an inadequate polymorphonu-
clear cell activity. As a consequence of the central role of 
the humoral response, it has recently been demonstrated 
how determining Toll Like Receptors (TLRs) , (mem-
brane and cytoplasmic receptors), are in modulating the 
innate response. These appear to be the main receptors 
of lipopetide molecules, of peptidoglycans and lopotei-
choic acid of the Gram+ bacteria. 
TLR-4 seems to have a specific role in mediating the 
pro-inflammatory action of Pneumococcal pneumolysi-
na, while TLR-2 seems to modulate the inflammation 
in the nervous system even during Pneumococcal infec-
tions. Finally, it has been determined that animals with 
TLR-9 deficiency are more susceptible to Pneumococ-
cal infections [8, 9].
The serotypic switch phenomenon  
and its causes
According to the peculiar structure of the capsule, 92 
serotypes of Pneumococcus with different capsular an-
tigenic characteristics can now be identified. There are 
differences in the distribution of serotypes between 
adults and children. In the latter, the most frequent se-
rotypes up to now appear to be 1, 19A, 3, 6A and 7F in 
which the antibiotic-resistance phenomenon is also fre-
quent. The serotypic distribution also varies according 
to the geographical region being studied. The environ-
ment, economic and hygenic conditions, different thera-
peutic and preventive strategies modulate the serotypic 
distribution, but in any case, the most invasive types are 
always predominant. Moreover, some serotypes seem to 
be exclusive of the carriers (16, 35B, 21).
As regards invasive forms, we know that most of them 
are caused by a few serotypes that prove to be those that 
are now included in the 13-valent conjugate vaccine 
(PCV13): 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F 
and 19A.
The heptavalent conjugate vaccine has been used since 
2000 when it was introduced into the USA for the first 
time. Some years after the introduction of the PCV7, a 
phenomenon of serotype replacement was pointed out: 
the so-called serotypic switch. This complex phenom-
enon has determined the replacement of 7 serotypes 
contained in the vaccine together with other less com-
mon ones, some of which are invasive or characterised 
by a high antibiotic-resistance. An increase in the isola-
tion of serotype 19A has been observed as well as non-
vaccinated strains such as 1 and 7F, an increase in the 
rarest serotypes such as 17, 29 and 38 and non-typable 
strains. The replacement, however, only depends on 
the vaccination to a small part [10, 11]. In fact, differ-
ent phenomena have been considered in order to ex-
plain this fact:
•	 Emergence	 of	 new	 serotypes	 on	 the	 epidemiologi-
cal scene. The vaccine seems to have favoured the 
colonisation of nasopharyngeal carriers by new sero-
types.
•	 Exposure	of	minority	serotypes	already	present	be-
fore the introduction of the vaccination. The vaccine 
that has determined the disappearance of the most 
common serotypes or at least greatly reducing their 
incidence, also allows for the detection of the minor-
ity strains so far “masked”.
•	 Serotypic	switch.	This	phenomenon	is	not	complete-
ly due to acquired vaccine immunity, but it depends 
on the intrinsic plasticity of the Pneumococcus [12]. 
Recently it has been possible to sequence the entire 
bacterial genome, containing more than 2 million 
bases and characterised by large regions of vari-
ability. During infection, in the carrier or also dur-
ing laboratory experiments, S. pneumoniae is able 
to acquire DNA fragments from other pneumococci 
or even from other bacteria (i.e. Streptococci). This 
allows for a modification of the serotypic character-
istics of the polysaccharide capsule and to acquire 
new qualities, among which the most dangerous is 
antibiotic-resistance. The micororganism becomes 
immune to antibiotic therapy and more virulent, ca-
pable of escaping the immune system: these recom-
binations give Pneumococcus an evolutionary ad-
vantage, that determines its selection [13]. 
•	 Replacement	of	serotypes	circulating	among	the	car-
riers for spontaneous secular trend [14].
The magnitude of the serotypic switch phenomenon was 
initially low, but over the years, it has gradually become 
more prevalent both in North American and Europe and 
in Italy, so as to partially erode the beneficial effect of 
PCV7. The observation of these replacement serotypes 
came about studying both the serotypes present in the 
naso-pharynx and the blood or spinal fluid samples from 
patients with invasive diseases.
There has been a sudden decrease in the number of in-
fections in the invasive forms with a consequent drop 
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in the death rate and post-event morbidity both in the 
population of individuals in a vaccinal age and in new-
borns under three months old and, therefore, too small 
to be vaccinated. Unfortunately, in this case, dividing 
the cases on the basis of the serotypes under discussion, 
a small increase of non-PCV7 has been registered along 
with a strong decrease in vaccinal serotypes. Actually, 
the replacement mechanism for some serotypes, for 
example 19A, is not in the various case histories. The 
serotype switch is more correlated to the secular trend 
replacement and to antibiotic resistance than to the in-
troduction of the vaccines. [15, 16]. The increase in the 
isolation of 19A deserves attention. Up until a few years 
ago it was rather rare and substantially harmless. The 
incidence of 19A has increased progressively (in 2005 
it reached 36%). In addition, unlike many serotypes 
that tend to privilege some forms compared to others, 
the Pneumococcus 19A can be found in all possible lo-
calisations: otitis, pneumonia, meningitis, and sepsis. 
Another aspect that characterises it is its distinct abil-
ity to develop resistance to penicillin, but also to other 
antibiotics. Preliminary analyses, as well, conducted 
on numerous serotypes 19A islolated in children with 
pneumococcus invasive infections (IPD) demonstrated a 
capsular switch with replacement, for example, of genes 
which were previously present in serotype 4. Today, 
the introduction of the new 13-valent conjugate vaccine 
contains all the hopes of epidemiologists and clinicians 
as regards both this phenotype and others not included 
in the PCV7.
The capsular-switch
Bacteria have a variable “sex life” that goes from celiba-
cy to an evident promiscuity, just like the Pneumococ-
cus . By “sex” we mean the occurence of homologous 
recombinations between bacteria of the same species 
or of different species. It has been demonstrated how 
frequent recombinations can determine rapid diversi-
fications in the different species while in those species 
that practice “celibacy”, these come about much more 
slowly and they depend on the accumulation of punc-
tiform mutations. This offers an important key to the 
interpretation of how these pathogens can rapidly de-
velop resistance to antibodies and even escape vaccinal 
protection. 
The short-term mutation rate in the various pathogen-
ic agents had a much higher result than was expected 
(about 10-6 replacements per site per year) even though 
it remains less compared to that of RNA virus.
Recent studies conducted on 240 isolated viruses 
obtained from 22 different countries from 1984 to 
2008 [17], have demonstrated how the S. pneumoniae 
has evolved over these 40 years and what its diffusion 
has been from one continent to another. Recombination 
is frequent in this species. In fact, 74% of the genome 
has undergone a recombination through replacement in 
at least one isolated virus. The most frequent phenom-
enon verified was the replacement of bases, even though 
deletions and insertions have been pointed out in some 
cases. As regards Pneumococcus, these phenomena have 
been underlined from among the different serotypes, but 
also with species of streptococci correlated with S. pneu-
moniae, among which Streptococcus mitis, Streptococ-
cus oralis and Streptococcus pseudopneumoniaie should 
be remembered [18].
Eliminating the recombinant areas, these studies offer 
the opportunity to identify the presence of genetic poly-
morphisms that are used to rebuild the phylogenesis of 
the bacterial strains, in this way, allowing one to map 
the dynamics of the acquisition and/or loss of antibiotic 
resistance and the alterations in the capsular serotypes. 
This opportunity to acquire information about the phy-
logenesis of the bacterial strains that have been studied, 
allows a demonstration of the course of the diffusion of 
the bacteria in different geographical areas over time 
and most of all, to indicate possible serotypic switches. 
Switches between 19A and 19F, like between 19A. 6A, 
3, 14 and 15B have, in fact, been recorded in significant 
amounts even after the introduction of the PCV7. The 
mechanisms responsible for the variation of the capsular 
serotype involve large loci that codify for the capsular 
polysaccharides. These replacements are interpreted as 
the consequence of the selection of the body’s immunity 
response or more recently, of the introduction of conju-
gate vaccines that have a restricted number of the more 
than 90 capsular serotypes known as their target. In ad-
dition, the capsular switch not only provides protection 
from specific antibodies in the population (for example 
for the vaccination itself), but it modifies susceptibility 
at the same time. In fact, some types of capsules bind 
fewer antibodies than others: the type 3 capsule of the 
D39 serotype, in fact, binds less than half of the anti-
bodies of type 2 of the same serotype, and in this way, 
increases virulence [5]. Different chromosomal areas are 
frequently substituted through recombinations and the 
area that seems to be more frequently involved is the one 
around the tetM gene in which the genes pspE, pspA and 
pspC are found. PspA and pspC are important proteins 
that are involved in the pathogenesis of Pneumococcus 
infections and they represent a potential target for vac-
cines as they are recognised by the antibodies produced 
during experimental studies on carriers. It has also been 
demonstrated how these genes can be very quickly re-
moved eliminated from the chromosomes proving how 
the pneumococcal population is capable of responding 
immediately to the introduction of direct vaccines based 
on antigenic proteins being developed now.
The development of antibiotic resistance
The same thing is true as regards the development of 
the resistance to antibiotics, where a fundamental role is 
carried out by the selection caused by humans. In fact, 
the scarce selection carried out by the use of aminoglu-
cosides and cloramphenicol has caused an occasional 
deletion of the loci responsible for the resistance to 
these antibiotics. On the contrary, resistance to penicil-
lin has frequently been acquired during phylogenesis 
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which perhaps represents the most important resistance 
to medicines for this class of bacteria. The fulcrum of 
the mechanism on which the resistance to penicillin is 
based is represented by the penicillin binding proteins 
(PBP) of which six types are known. Mutations at the 
gene level that codify for these proteins are responsible 
for a low, moderate or high resistance to this class of 
antibiotics estimated on the basis of MIC.
The genes responsible for the synthesis of PBP are 
pbp1a, pbp2b, pbp2x and pbp2a. The genetics of the 
mechanisms that lead to the development of this resist-
ance are very complex and regard forms of mosaicism of 
these genes. It is of fundamental importance to remem-
ber, since it determines a correlation between the phe-
nomenon of the resistance to medicines and the capsular 
switch, that the two genes most frequently involved in 
determining the resistance to penicillin, i.e. Pbp2x and 
pbp1a, are located in the same area of the genome where 
the genes that determine the capsular serotype are located 
which are found between the dexB and aliA genes. This 
can be proved by the fact that among the non- vaccinal 
serotypes that are more frequently observed in patients 
and carriers, we find 19A, which is sometimes the conse-
quence of a capsular switch between this and 19F or 4. At 
the same time 19A proves to be one of the serotypes that 
presents the strongest resistance to penicillin and often to 
other medicines. Other serotypes that are known for their 
resistance to penicillin are 23, 6, 9 and 14 [19, 20].
Through phylogenesis, the resistance to macrolides has 
also been acquired determined by the methylation of the 
targets of ribosomal RNA of the subunity 23S, in this 
way, facilitating the synthesis of a specific pump for the 
removal of these medicines called mef (macrolid efflus-
type efflux pump). The same is true for another pump, 
the mef/mel-type efflux pump. In addition, it has been 
demonstrated how a strong association exists between 
resistance and macrolides and resistance to clindamycin, 
caused by alterations the ribosomal subunity 50S [21]. 
Finally, numerous studies have indicated considerable 
changes in the resistance of the Pneumococcus as regards 
various antibiotics, above all for non-vaccinal serotypes 
after the introduction of the PCV7. In the last years, in 
fact, we have witnessed a decrease in the resistance to 
Trimethoprim-Sulphamethoxazolo and to cefalosporine 
(such as Ceftriaxone) and cases of a high resistance to 
penicillin have also decreased. On the contrary, the in-
termediate resistance to penicillin has increased just like 
the resistance to macrolides and clindamicines. Finally, 
the isolation of multi-resistant bacterial strains (> 3 anti-
biotics) has also increased [22].
The role of the carrier
We must not forget what a fundamental role the carrier 
plays in a reality like this. The preeminent carrier of S. 
pneumoniae is represented by a young child where it is 
more frequently isolated in the nasopharynx.
The alterations in the distribution of bacterial serotypes 
is inextricably connected to the distribution of Pneu-
mococcus in children where the colonisation rates are 
highest. In this way, these young patients become natu-
ral reservoirs for invasive species as well, offering an 
optimal environment for the evolution of this pathogenic 
agent. It, therefore, becomes crucial to recognise and un-
derstand the changes in the bacterial populations in these 
individuals who are subject to the use of an antibiotic 
and the universal immunisation exercised through vac-
cinations that have reached important levels in the pedi-
atric populations [22].
As we know, what is called the colonisation of the mu-
cous membrance takes place in the carrier. To carry this 
out, it is of utmost importance for the bacteria to adhere 
efficaciously to the epithelial surface. In this case, the 
Pneumococcus capsule represents an obstacle that im-
pedes an optimal adhesion. In fact, it has been demon-
strated that during the colonisation phase of the mucous 
membrane, especially for bacteria that are in close con-
tact with the epitheliums, the pathogen loses its own cap-
sule. This means escaping from the main defence against 
the Pneumococcus, represented by the anti-capsular an-
tibodies, and at the same time, making it impossible to 
locate the germ using non-molecular methods [23].
In addition, where different colonies of Pneumococcus 
are present in a carrier, there is a risk of possible recom-
binations that would allow a possible capsular switch, 
in this way giving a greater pathogenicity and resistance 
to the defences of the host to one of the strains present, 
increasing the risk of developing an invasion and, there-
fore infection,
Like in invasive diseases, an important phenomenon of 
the serotypic switch has also been observed in the car-
rier that recognises the same possible causes indicated 
previously. In particular, after the introduction of PCV7, 
there has been a progressive increase in the isolation of 
non-vaccinal serotypes especially 19A, 35B,23A and 
15B/C [22].
Today we still do not know to what extent the introduc-
tion of the conjugate vaccine can favour a serotypic and 
capsular switch, but it has, however, been proved that 
this can take place [24].
Conclusions
In conclusion, we can affirm that Pneumococcus is a 
very skilled pathogen that evolves over a very short time 
period. Frequent recombinations, as a consequence, lead 
to a rapid evolution of strains that are multiresistant to 
antibiotics and able to escape from the effects of specific 
vaccines against single proteinic antigens. 
Therefore, it is of utmost importance to promote and 
optimize a continual surveillance of S. pneumoniae in-
fections in all countries including those in which the 
antipneumococcal vaccination has not been scheduled 
yet. Without a doubt, molecular diagnostic techniques, 
such as PCR and MLST (Multi Locus Sequence Typ-
ing), are fundamental in reaching this objective and they 
constitute an essential approach to obtain information 
concerning the composition and evolution of bacterial 
species, offering a key for a better understanding of the 
pathogenic response to new antibiotics and vaccines.
streptOCOCCus pNeumONiae
93
n	 Received on March 11, 2012. Accepted on March 26, 2012.
n	 Correspondence: Chiara Azzari, Department of Pediatrics, Anna 
Meyer Children’s University Hospital, viale Pieraccini 24, 50139 
Florence, Italy - E-mail: c.azzari@meyer.it.
References
[1] Barocchi MA, Ries J, Zogaj X, et al. A pneumococcal pilus in-
fluences virulence and host inflammatory responses. Proc Natl 
Acad Sci USA 2006;103:2857-62.
[2] Hammerschmidt S, Wolff S, Hocke A, et al. Illustration of 
pneumococcal polysaccharide capsule during adherence and 
invasion of epithelial cells. Infect Immun 2005;73:4653-67.
[3] Angel CS, Ruzek M, Hostetter MK. Degradation of C3 by 
Streptococcus pneumonia. J Infect Dis 1994;170:600-8.
[4] Chudwin DS, Artip SG, Koremblit A, et al. Correlation of se-
rum opsonins with in vitro phagocytosis of Streptococcus pneu-
monia by polymorphonuclear leukocytes. J Infect Dis 1986;164: 
619-26.
[5] Abeyta M, Hardy GG, Yother J, et al. Genetic alteration of 
capsule type but not PspA type affects accessibility of surface-
bound complement and surface antigens of streptococcus pneu-
monia. Infect Immun 2003;71:218-25.
[6] Nelson AL, Roche AM, Gould JM, et al. Capsule enhances 
pneumococcal colonization by limiting mucus-mediated clear-
ance. Infect Immun 2007;75:83-90.
[7] Quin LR, Moore QC, McDaniel LS, et al. Pneumolisyn, PspA, 
and PspC contribute to pneumococcal evasion of early innate 
immune responses during bacteremia in mice. Infect Immun 
2007;75:2067-70.
[8] Hoffmann O, Braun JS, Becker D, et al. TLR2 medi-
ates neuroinflammation and neuronal damage. J Immunol 
2007;178:6476-81.
[9] Albiger B, Dahlberg S, Sandgren A. Toll-like receptor 9 acts at 
an early stage in host defence against pneumococcal infection. 
Cell Microbiol 2007;9:633-44.
[10] Who. Position paper. 23 march 2007, 82nd year No.12, 
2007;82:93-104.
[11] Steenhoff A, Shah SS, Ratner AJ, et al. Emergence of vaccine-
related pneumococcal serotypes as a cause of bacteremia. Clin 
Infect Dis 2006;42:907-14.
[12] Coffey TJ, Dowson CG, Daniels M, et al. Horizontal transfer of 
multiple penicillin-binding protein genes, and capsular biosyn-
thetic genes, in natural populations of Streptococcus pneumo-
niae. Mol Microbiol 1991;5:2255-60.
[13] Gherardi G, Whitney CG, Facklam RR, et al. Major related sets 
of antibiotic-resistent pneumococci in the United States as de-
termined by pulsed-field gel electrophoresis and pbp1a-pbp2b-
pbp2x-dhf restriction profile. J Infect Dis 2000;181:216-29.
[14] Butler JC, Breiman RF, Lipman HB, et al. Serotype Distribution 
of Streptococcus pneumoniae infections among preschool chil-
dren in the United States, 1978-1994: implications for develop-
ment of a conjugate vaccine. J Infect Dis 1995;171:885-9.
[15] Dagan R, et al. Replacement indipendent of vaccine pressure. 
47th  ICAAC, Chicago, September 17-20, 2007.
[16] Dagan R, Givon-Lavi N, Leibovitz E, et al. Introduction and 
proliferation of multidrug-resistant Streptococcus pneumoniae 
serotype 19A clones that cause acute otitis media in an unvac-
cinated population. J Infect Dis 2009;199:776-85.
[17] Croucher NJ, Harris SR, Fraser C, et al. Rapid pneumococ-
cal evolution in response to clinical interventions. Science 
2001;331 430-4.
[18] Hanage WP, Fraser C, Tang J, et al. Hyper-ricombination, di-
versity, and antibiotic resistance in pneumococcus. Science 
2009; 324:1454-7.
[19] McGee L, Mc Dougal L, Zhou J, et al. Nomenclature of major 
antimicrobial-resistance clones of streptococcus pneumoniae 
defined by the pneumococcal molecular epidemiology network. 
J Clin Microbiol 2001;39:2565-71.
[20] Brueggemann AB, Pai R, Crook DW, et al. Vaccine Escape 
recombinants emerge after pneumococcal vaccination in the 
United States. Plos Pathogens 2007;3:1628-36.
[21] Huang SS, Platt R, Rifas-Shiman SL, et al. Post-PCV7 Changes 
in colonizing pneumococcal serotypes in 16 Massachusetts 
communities, 2001 and 2004. Pediatrics 2005;113:408-13.
[22] Huang SS, Hinrichsen VL, Stevenson AE, et al. Continued im-
pact of pneumococcal conjugate vaccine on carriage in young 
children. Pediatrics 2009;124:1-11.
[23] Werno AM, Murdoch DR. Medical microbiology: laboratory 
diagnosis of invasive pneumococcal disease. Clin Infect Dis 
2008;46:926-32. 
[24] Lipsitch M, O’Neill K, Cordy D, et al. Strain characteristics of 
Streptococcus pneumoniae carriage and invasive disease isolates 
during a cluster-randomized clinical trial of the 7-valent pneu-
mococcal conjugate vaccine. J Infect Dis 2007;196:1221-7. 
